Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Viral Vectors
Sort By
Newest First
1 / 4
1 / 4
CDMO
Innovating and Collaborating to Support Biopharma Beyond the Typical CDMO
Janet Hoogstraate, Ph.D.
NorthX Biologics
PAO-10-24-CL-07
Oct 07, 2024
Gene Editing
MegaBulb DNA: a Non-Viral ssDNA Breakthrough Revolutionizing Gene Editing
Tom Adie, Ph.D.; Elena Stoyanova, Ph.D.
Touchlight
PAO-20-24-CL-01
Sep 30, 2024
dbDNA
Revolutionizing the Genetic Medicine Landscape with Enzymatic DNA
Jill Makin
Touchlight
PAO-08-24-CL-01
Aug 19, 2024
AAV
Overcoming Variability and Scaling Challenges in AAV Manufacturing
Rafal Garus
Viralgen Vector Core
PAO-08-24-CL-03
Jul 22, 2024
Cell Therapy
Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA
Genezen
PR-07-24-NI-01
Jul 02, 2024
Synthetic DNA
Transforming the Economics of AAV Manufacture While Optimizing Quality with dbDNA
Tom Merritt, Ph.D.
Touchlight
PAO-07-24-CL-01
Jul 02, 2024
Cell and Gene Therapy Regulatory
Navigating Regulatory Complexity for Cell and Gene Therapies
Natasha Rivas
PAO-04-24-CL-03
Apr 12, 2024
Viral Vectors
A Viral Vector CDMO Vision that Resonates
Drew Brennan; Chris Berger; Elie Hanania, Ph.D.; Dave Ingamells; Rami Barghout, PE
Avid Bioservices
PAO-03-24-CL-06
Mar 14, 2024
Plasmid Manufacturing
Optimizing Plasmid Production to Meet Growing Demand
Cynthia A. Challener, Ph.D.; Danielle Alvarez
Pharma's Almanac
PAO-04-23-NI-01
Apr 03, 2023
Viral Vector Manufacturing
Considerations in Viral Vector Analytical Development to Enable Smooth Transfer to Quality Control
Chris Berger; Kilian Witzel
Avid Bioservices
PAO-02-23-CL-03
Mar 14, 2023
AAV Capsid Engineering
Expanding Patient Access to Gene Therapies through AAV Capsid Engineering
Damien Marsic, Ph.D.
Porton Advanced Solutions
PAO-01-23-CL-02-155
Feb 06, 2023
Viral Vector Manufacturing
Optimizing Transient Transfection for Viral Vector Production
Cynthia A. Challener, Ph.D.; David Alvaro, Ph.D.
Pharma's Almanac
PAO-11-022-NI-09
Nov 15, 2022
Viral Vectors
Risk-Based Optimization of Viral Vector Processes Adds Real Value
Elie Hanania, Ph.D.; Tatiana Mello, M.S.
Avid Bioservices
PAO-09-022-CL-05
Oct 25, 2022
Cell and Gene Therapy
State of the Cell and Gene Therapy Market
James Grote
Nice Insight
PAO-10-022-NI-01
Oct 11, 2022
Column: M&A
Who's Left to Acquire in CDMO Biomanufacturing? A Select Few.
Nigel Walker
Nice Insight
PAO-06-022--NI-12
Jun 24, 2022
Cell and Gene Therapy Analytics
Accelerating the Development of High-Quality Cell and Gene Therapies with Comprehensive, In-house Analytical Support
Hui Chen, Ph.D.
Porton Advanced Solutions
PAO-06-022-CL-07
Jun 21, 2022
Viral Vector Manufacturing
Avid Bioservices, Inc. and CRB Highlight Efforts that Enabled Opening of First Phase of New Viral Vector Facility in California in Only Eight Months
Avid Bioservices
PR-M06-22-05
Jun 16, 2022
New Facility
AGC Biologics Invests in Viral Vector Suspension at New U.S. Campus
AGC Biologics
PR-M05-22-13-359
May 18, 2022
Viral Vector Manufacturing
Approaching Viral Vector Manufacturing With an Emphasis on Quality and Design
Chris Berger; Atef Khezri
Avid Bioservices
PAO-05-022-CL-02
May 10, 2022
GMP Certification
GMP Certification for Exothera Further Extends its Viral Vector Manufacturing Capacity
Exothera
PR-M03-22-10
Mar 23, 2022